Recent Updates
Recently added Catalysts
FDMT Neutral Sentiment

4DMT Company Updates

Key Takeaway: The article provides an overview of recent updates related to 4DMT and other companies in the ophthalmology sector. It highlights various developments, including FDA approvals and product launches. The content is primarily focused on industry advancements without specific emphasis on 4DMT's unique contributions or challenges.
Price reaction · baseline $10.7 (2025-12-03 close) · hit pre-market · 2 other FDMT headline(s) in the window, move may be shared
day 0 close · peak
+4.6%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration

Full Press Release Details

EyewireTV | 11.05.2025

Now Playing

Introduction

Share
|
Copy Link

Astellas

Share
|
Copy Link

Apellis Pharmaceuticals

Share
|
Copy Link

Oculis

Share
|
Copy Link

Ocular Therapeutix

Share
|
Copy Link

Nanoscope Therapeutics

Share
|
Copy Link

Neurotech

Share
|
Copy Link

EyePoint Pharma

Share
|
Copy Link

EyeBio

Share
|
Copy Link

4DMT

Share
|
Copy Link

Previous EyewireTV Episodes

Introduction

FDA Approves Viridian Therapeutics' Lumvoa for Thyroid Eye Disease (TED)

Lucentis Biosimilar Byooviz Relaunched in US

Lumibird Introduces Integre LIO Wireless Integrated Laser Indirect Ophthalmoscope

Introduction

Ocular Therapeutix Provides Key Update on NDA Submission Plans for Axpaxli

Thea US Announces US Launch of Zolymbus Preservative-Free Gel for Glaucoma

Update on Clinical Development Advancements for Novel Drug Candidates

Introduction

J&J Announces Full Market Availability of Tecnis PureSee IOL in US

Bayer Completes Acquisition of Perfuse Therapeutics

Ophthalmic Leaders Discuss Regulatory Environment in the US

Introduction

International Study Examines Semaglutide and Wet AMD Risk

Heidelberg Receives FDA Clearance for Spectralis Software Update

B+L Launches Blink Triple Care Preservative Free for Dry Eye

Introduction

Oculis' DME Eye Drop Candidate Does Not Meet Primary Endpoint in Phase 3 Trials

Rayner Launches Ophteis Cohesive OVD in Europe

Samsung Bioepis Launches Eylea Biosimilar Opuviz in Europe

Introduction

Outlook Wins FDA Appeal of Lytenava for Wet AMD; Plans BLA Submission

First Commercial FLIGHT Procedures Using ViaLuxe Laser System Performed in Europe

Oculus Introduces Meibo Analytics AI-Assisted Tool for MGD

Introduction

FDA Clears Next-Generation FSYX Ocular Pressure Adjusting Pump

B+L Launches PreserVision AREDS3 Eye Vitamins in the US

Strategic Advisor Discusses Regulation Environment for Industry and Physicians

Introduction

Future of Regenerative Medicine

Update on AI Use and Innovation

Next-Generation Therapies

Introduction

Bayer Expands Ophthalmology Pipeline with Acquisiton of Perfuse Therapeutics

Viridian Announces REVEAL-2 Phase 3 Data for TED Treatment Elegrobart

Steven Dell, MD, Discusses Impact of Declining Medicare Reimbursement

Introduction

Brent Saunders, Bausch + Lomb

Julie Brewer, Alcon

Mark Baum, Harrow

Introduction

Glaukos Launches Epioxa for Keratoconus; Secures J-Code

BVI Receives CE Mark for Virtuoso Phaco-Vitrectomy Surgical System

ASCRS Executive Director Recaps Annual Sightline Meeting

Introduction

J&J Tecnis PureSee EDOF IOL

Alcon Clareon TruPlus IOL

Oculus Pentacam Cornea OCT

Introduction

Massive Recall Issued for Several OTC Store-Brand Eye Drops

Dosing Intervals for Eylea HD Extended Up to Every 20 Weeks

B+L's Preloaded enVista Envy Full Range of Vision IOL Launched in Europe

Introduction

Biogen Enters Agreement to Acquire Apellis for $5.6 Billion

TenPoint Launches Presbyopia Drop Yuvezzi in US

Kodiak Sciences Releases Phase 3 Data on DR Drug Candidate Zenkuda

Introduction

2026 ASCRS Annual Meeting

Sightline Meeting Preview

Identifying Ophthalmology Trends

Introduction

Alcon and Lensar Terminate Proposed Merger

FDA Approves J&J's Tecnis PureSee EDOF IOL

Aldeyra Receives Third CRL for Investigational DED Drug Reproxalap

Introduction

Cassini Guidance System Receives Approval in Europe

NovaBridge Presents New Data for Investigational Wet AMD Therapy

Visionix VX 40 Pro Available for Pre-Sale at Vision Expo 2026

Introduction

Supplemental NDA of Phentolamine for Presbyopia Accepted by FDA

Eye PCR Receives CE Mark for fixOflex Endocapsular Device

Rayner Acquires US Distribution Rights to OVD Anikavisc

Introduction

Zeiss Releases Software App to Address Challenges in Ophthalmic Care

Oertli Launches OS 4 Up for Cataract and Vitreoretinal Surgery in Europe

Harrow Introduces PharmaPack Direct-to-Prescriber Cash-Pay Kits for Ophthalmic Medications

Introduction

Ocular Therapeutix Reports Positive Phase 3 Superiority Trial Results for Axpaxli for Wet AMD

Nordic Pharma Dry Eye Therapy Lacrifill Now Available in Europe

Alcon Launches TOTAL30 Multifocal for Astigmatism in US

Introduction

New Research Reveals Metformin May Lower Risk of AMD Progression

Study Examines Performance of Large Language Models on Ophthalmology Exams

Doctor-Led Alliance to Support Private Practice Optometrists Launches

Introduction

FDA Approves Yuvezzi, First Dual-Agent Eye Drop for Presbyopia

Rayner Launches AI-Powered Patient Education Platform Eyejourney

Study Examines Association Between Sleep Positioning and Eye Pressure

Introduction

FDA Approves NDA Supplement for Re-Administration of iDose TR

Nidek Launches Phantom Open-Field Refraction System in EU

Review of Recent Leadership Changes in Ophthalmology

Introduction

Rayner Receives FDA 510(k) Clearance for Sophi Phaco System

Eylea 8 mg Approved in Europe for Third Indication

Mu Medical Established After Consolidation Plan

Introduction

Study Reveals Widely Used Eye Injection Can Treat Hypotony

FDA Clears First Daily Disposable Soft EDOF Contact Lens for Presbyopia

Clinical Development Updates for Retinal Disease Drug Candidates

Introduction

Study Reveals Widely Used Eye Injection Can Treat Hypotony

FDA Clears First Daily Disposable Soft EDOF Contact Lens for Presbyopia

Clinical Development Updates for Retinal Disease Drug Candidates

Introduction

Merger Agreement Between Alcon and Staar Surgical Terminated

FDA Issues Another CRL to Outlook for Wet AMD Candidate

Lucentis Biosimilar Nufymco Approved by FDA

Introduction

July

August

September

Introduction

January

February

March

Introduction

Aldeyra Provides Updates on Timing of PDUFA Date for Reproxalap

Ocular Therapeutix to Pursue Accelerated NDA Pathway for Axpaxli

Companies with Late-Stage Drug Candidates Announce FDA Submission Plans

Introduction

Companies with Novel Glaucoma Technologies Reach Clinical Milestones

Haag-Streit Launches the Eyesi Indirect ROP Laser Module

EyeYon Medical to Initiate US Clinical Study of the EndoArt Corneal Implant

Introduction

Eylea HD Gains FDA Approval for New Indication and Dosing Schedule

Byooviz, Biosimilar to Lucentis, Approved in Europe as Pre-Filled Syringe

Phase 3 Results for Belite Bio's Stargardt Disease Drug Candidate

Introduction

Emerging Technologies in Glaucoma

Vialase FLIGHT Procedure

Bausch + Lomb Elios

Introduction

B+L Outlines Strategic Path to Innovation and Growth at Investor Day

Apellis Reports 5-Year Data Examining Syfovre and GA Progression

Two Global Organizations for Restoring Sight Merge

Introduction

Sydnexis and Santen Receive Approval for Myopia Treatment Ryjunea in the UK

Lilly Makes Two Deals to Acquire Investigational Gene Therapies for IRDs

Nanoscope Reports Long-Term Data for Optogenetic Therapy Candidate for RP

Introduction

Alcon

Bausch + Lomb

Johnson & Johnson

Introduction

Glaukos Epioxa

Iantrek AlloFlo Uveo

Lumenis Digital Duet 2.0

Introduction

Uday Devgan, MD, Shares Experience Performing World’s First Robotic Cataract Surgery

Konan Medical Receives CE Mark for objectiveFIELD Analyzer

Biotech Healthcare Launches Optiflex XTENSE Comfort Plus EDOF IOL

Introduction

Presbyopia Eye Drop Vizz Now Commercially Available

Lumibird Introduces ICL Guru Integration for ABSolu Ultrasound Platform

Update on Gene Therapy Candidates for Retinal Diseases

Introduction

Iantrek

PLU Ophthalmic

SpyGlass Pharma

Introduction

Amaros

Atia Vision

Aurion Biotech

Introduction

Roche Contivue with Susvimo

Alcon Product Launches

Glaukos iStent infinite

Introduction

Purpose of National Eye Institute

NEI Contributions

Impact of NEI Consolidation

Introduction

Clinical Updates of Investigational Treatments for Retinal Diseases

Nicox Provides Phase 3 Results for Investigational Glaucoma Eye Drop

First-in-Human Implantation of Ocumetics Lens Accommodating IOL

Introduction

Ciliatech Obtains CE Certification for Intercil Uveal Spacer for Glaucoma

Zeiss Receives CE Mark for Cirrus PathFinder AI Tool with Automated OCT Assessment

FDA Provides Update on Target Action Dates of Two Eylea HD Submissions

Introduction

Goals of the TFOS DEWS III Report

Treatment Algorithms

Collaborative Effort

Introduction

Charles Wykoff, MD, Shares Experience Performing First Commercial Surgeries for MacTel

VSY Biotechnology Launches Enova Hydrophobic IOLs with the Rotary jet Delivery System

Altris Sync App Allows to AI to Sync Directly to OCT Devices

Introduction

Alcon Boosts Refractive Portfolio with Acquisition of Staar Surgical

Lenz Therapeutics CEO Discusses FDA Approval of Vizz Presbyopia Drop

Optical Industry Braces for Changes as New Reciprocal Tariffs Begin

Introduction

Alcon Announces US Commercial Availability of Tryptyr for Dry Eye Disease

Boehringer Ingelheim and Re-Vana Therapeutics Enter $1B Collaboration

Companies with AMD Drug Candidates Complete Phase 3 Enrollment

Introduction

Alcon Announces US Commercial Availability of Tryptyr for Dry Eye Disease

Boehringer Ingelheim and Re-Vana Therapeutics Enter $1B Collaboration

Companies with AMD Drug Candidates Complete Phase 3 Enrollment

Introduction

Harrow Adds Biosimilars to Portfolio After Deal with Samsung Bioepis

Nanoscope Initiates Rolling Submission of Gene Therapy for RP

FDA Accepts Aldeyra's Resubmitted NDA for Reproxalap

Introduction

AECOS Summer Symposium

Kendall Donaldson, MD

Cathleen McCabe, MD

Introduction

Alcon Acquires LumiThera, Maker of PBM Device for Dry AMD

European Commission Approves Eylea 8 mg for Extended Treatment Intervals

Myopia Management: The Business of Ophthalmology or Optometry?

Last updated: Dec 4, 2025